GPR17

Across TCGA pan-cancer cohorts, GPR17 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of GPR17’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where GPR17 RNA is repressed in tumor relative to normal tissue. In most cancer types GPR17 is over-expressed in tumor, although a few such as BLCA and KICH show the opposite, repressed pattern.

BLCA, KICH, and LUAD are the cancer types where GPR17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GPR17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−1.852	<.001	11	view →
KICH	Male	All	−1.093	<.001	10	view →
LUAD	Female	III,IV	−1.504	<.001	9	view →
KIRP	Male	All	−0.936	<.001	9	view →
LUSC	Female	All	−1.984	<.001	8	view →
COAD	Male	All	−0.892	<.001	8	view →
BRCA	All	III,IV	−1.391	<.001	6	view →
UCEC	All	All	−1.047	<.001	6	view →
THCA	All	All	−0.181	.010	6	view →
KIRC	Male	II,III,IV	−0.348	.001	4	view →
STAD	Female	All	−1.287	.002	3	view →
READ	All	All	−1.003	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

GPR17–BLCA

Open the BLCA breakdown →